FDA approves Daiichi Sankyo’s Turalio for rare joint tumour

This article was originally published here

The approval for Turalio is for the treatment of adults with rare joint tumour associated with severe morbidity or functional limitations and is not responsive to improvement through

The post FDA approves Daiichi Sankyo’s Turalio for rare joint tumour appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply